CD133 and Ki‑67 expression is associated with gastrointestinal stromal tumor prognosis

Lu,Canrong; Liu,Licheng; Wu,Xin; Xu,Wentong

doi:10.3892/ol.2013.1564

CD133 and Ki‑67 expression is associated with gastrointestinal stromal tumor prognosis

Authors:
- Canrong Lu
- Licheng Liu
- Xin Wu
- Wentong Xu
View Affiliations

Affiliations: Department of General Surgery, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: September 5, 2013 https://doi.org/10.3892/ol.2013.1564
Pages: 1289-1294

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD133+ tumor cells have a greater potential ability for tumorigenesis, proliferation, invasion and metastasis compared with CD133- tumor cells. Ki‑67 is associated with cell proliferation in various tumors and has a markedly positive correlation with the prognosis of patients. However, there are a limited number of studies that have investigated the association between the prognosis of gastrointestinal stromal tumors (GISTs) and the two markers. The present study aimed to investigate CD133 and Ki‑67 expression in GISTs and to explore their clinicopathological significance in the prognosis of patients with GISTs. A total of 111 GIST patients from the Chinese People's Liberation Army (PLA) General Hospital were retrospectively followed up and immunohistochemistry was used to detect CD133, Ki‑67 and CD117 expression in the tumor samples. The survival rates of the patients were analyzed using the Kaplan‑Meier method. The log‑rank test, χ2 test and Cox's proportional hazards model were used to determine the association between CD133, Ki‑67, CD117 expression and the prognosis of GIST. The 1‑, 3‑ and 5‑year survival rates were 93.0, 89.0 and 82.0%, respectively, in all the patients. However, in the patients with CD133+ or Ki‑67+, the 1‑, 3‑ and 5‑year survival rates were 81.0, 61.5 and 50.0% and 83.0, 66.6 and 53.0%, respectively. Compared with the negative groups, the survival rates in the positive groups were statistically lower (CD133 log‑rank, P=0.028; Ki‑67 log‑rank, P=0.002). The multivariate Cox analysis revealed that CD133 and Ki‑67 expression were considerable factors in the prognosis of GIST patients (CD117, P=0.495; CD133, P=0.036; Ki‑67, P=0.003). In conclusion, the positive expression of CD133 and Ki‑67 was associated with a poor prognosis of GIST.

View Figures

View References

1	Gupta P, Tewari M and Shukla HS: Gastrointestinal stromal tumors. Surg Oncol. 17:129–138. 2008. View Article : Google Scholar
2	Katz SC and DeMatteo RP: Gastrointestinal stromal tumors and leiomyosarcomas. J Surg Oncol. 97:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
3	Delahaye NF, Rusakiewicz S, Martins I, et al: Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 17:700–707. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kikuta K, Kubota D, Saito T, et al: Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor. J Proteomics. 75:1089–1098. 2012. View Article : Google Scholar : PubMed/NCBI
5	González-Cámpora R, Delgado MD, Amate AH, et al: Old and new immunohistochemical markers for the diagnosis of gastrointestinal stromal tumors. Anal Quant Cytol Histol. 33:1–11. 2011.PubMed/NCBI
6	Zong L, Chen P and Xu Y: Correlation between P53 expression and malignant risk of gastrointestinal stromal tumors: evidence from 9 studies. Eur J Surg Oncol. 38:189–195. 2012. View Article : Google Scholar : PubMed/NCBI
7	de Oliveira AT, Pinheiro C, Longatto-Filho A, et al: Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr. 44:171–178. 2012.PubMed/NCBI
8	Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
9	Shmelkov SV, St Clair R, Lyden D and Rafii S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 37:715–719. 2005. View Article : Google Scholar : PubMed/NCBI
10	Chen YC, Hsu HS, Chen YW, et al: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE. 3:e26372008. View Article : Google Scholar : PubMed/NCBI
11	Matsumoto K, Arao T, Tanaka K, et al: mTOR signal and hypoxiainducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res. 69:7160–7164. 2009. View Article : Google Scholar : PubMed/NCBI
12	Qin K, Jiang X, Zou Y, et al: Study on the proliferation and drug resistance of human brain tumor stem like cells. Cell Mol Neurobiol. 30:955–960. 2010. View Article : Google Scholar : PubMed/NCBI
13	Moriyama T, Ohuchida K, Mizumoto K, et al: Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal cells. Cancer. 116:3357–3368. 2010.
14	Ding W, You H, Dang H, et al: Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology. 52:945–953. 2010. View Article : Google Scholar : PubMed/NCBI
15	Arne G, Kristiansson E, Nerman O, et al: Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer. 129:1149–1161. 2011. View Article : Google Scholar : PubMed/NCBI
16	Wong NA, Young R, Malcomson RD, et al: Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 43:118–126. 2003. View Article : Google Scholar : PubMed/NCBI
17	Nakamura N, Yamamoto H, Yao T, et al: Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol. 36:828–837. 2005. View Article : Google Scholar : PubMed/NCBI
18	Miettinen M and Lasota J: KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 13:205–220. 2005. View Article : Google Scholar : PubMed/NCBI
19	Elias J: Immunhistopathology: A Practical Approach to Diagnosis. ASCP Press; Chicago, IL: 1990
20	Taylor CR: Immunoperoxidase techniques: practical and theoretical aspects. Arch Pathol Lab Med. 102:113–121. 1978.PubMed/NCBI
21	Joensuu H: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 39:1411–1419. 2008. View Article : Google Scholar : PubMed/NCBI
22	Dematteo RP: Personalized therapy: prognostic factors in gastrointestinal stromal tumor (GIST). J Gastrointest Surg. 16:1645–1647. 2012. View Article : Google Scholar : PubMed/NCBI
23	McCarter MD, Antonescu CR, Ballman KV, et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant Gist Study Team. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. 215:53–59. 2012. View Article : Google Scholar
24	Attili SV, Ananda B, Mandapal T, et al: Factors influencing progression-free survival in gastrointestinal stromal tumors with special reference to pathologic features, cytogenetics, and radiologic response. Gastrointest Cancer Res. 4:173–177. 2011.
25	Weigmann A, Corbeil D, Hellwig A and Huttner WB: Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of nonepithelial cells. Proc Natl Acad Sci USA. 94:12425–12430. 1997. View Article : Google Scholar
26	Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
27	Chew MF, Teoh KH and Cheah PL: CD133 marks for colorectal adenocarcinoma. Malays J Pathol. 34:25–28. 2012.PubMed/NCBI
28	Reggiani Bonetti L, Migaldi M, Caredda E, et al: Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Scand J Gastroenterol. 47:1211–1217. 2012.PubMed/NCBI
29	Hutchins JR, Toyoda Y, Hegemann B, et al: Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science. 328:593–599. 2010. View Article : Google Scholar : PubMed/NCBI
30	Artigiani Neto R, Logullo AF, Stávale JN and Lourenço LG: Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST). Acta Cir Bras. 27:315–321. 2012.PubMed/NCBI
31	Lamba G, Ambrale S, Lee B, et al: Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol. 5:212012. View Article : Google Scholar : PubMed/NCBI